Requested article is recognized. But, there is no holdings information available for it.
A notification was automatically sent to our data department to investigate. The information below was supplied.
Please check in a few days to see if it has been corrected.
Article:Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Source:Yearbook of Surgery, Volume 2012, Issue null, Pages 184-186